Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
Hematological Oncology · 2025
DOI: 10.1002/hon.70006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Allison M Bock und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Drug Resistance, Neoplasm, Mutation, DNA-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Tanoto Foundation, Predolin Foundation Biobank.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify patients that will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated the genomic landscape of PTR and compared it to that of non‐PTR DLBCL. We found a significant increase in the frequency of TP53 (34% vs. 15%, p = 0.005) and ARID1A mutations (21% vs. 7%, p = 0.007) in PTR cases, with pathway analysis further demonstrating a downregulation of TP53 and an increase in chromatin modifying pathways. These results suggest that TP53 and ARID1A may be key mediators of PTR and important pathways contributing to the poor outcomes. We found that the current molecular classifiers were unable to identify PTR cases at diagnosis. However, our newly identified high‐risk signature identified 46% of PTR cases at diagnosis. Overall, these results contribute to our understanding of the genomic landscape of patients with primary treatment resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
- Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Translational Medicine Hematology, Bristol Myers Squibb, Summit, New Jersey, USA.
- Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, New Jersey, USA.
- Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
- Informatics and Predictive Sciences, Bristol Myers Squibb, Seville, Spain.
ORCID-Profile: Allison M Bock, Melissa A Hopper, Abigail R Dropik, Yucai Wang, Thomas E Witzig
Förderung
- NIAID NIH HHS
- Tanoto Foundation
- Predolin Foundation Biobank
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Bock, A. M., Wenzl, K., Novak, J. P., Stokes, M. E., Hopper, M. A., Krull, J. E., Dropik, A. R., Sarangi, V., Ortiz, M., Stong, N., Huang, C. C., Maurer, M. J., King, R. L., Farooq, U., Wang, Y., Witzig, T. E., Ansell, S. M., Habermann, T. M., Cerhan, J. R., …, & Novak, A. J. (2025). Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance. Hematological Oncology. https://doi.org/10.1002/hon.70006
Vancouver
Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, et al. Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance. Hematological Oncology. 2025. doi:10.1002/hon.70006
BibTeX
@article{Bock2025,
author = {Bock, Allison M and Wenzl, Kerstin and Novak, Joseph P and Stokes, Matthew E and Hopper, Melissa A and Krull, Jordan E and Dropik, Abigail R and Sarangi, Vivek and Ortiz, Maria and Stong, Nicholas and Huang, C Chris and Maurer, Matthew J and King, Rebecca L and Farooq, Umar and Wang, Yucai and Witzig, Thomas E and Ansell, Stephen M and Habermann, Thomas M and Cerhan, James R and Gandhi, Anita K and Nowakowski, Grzegorz and Novak, Anne J},
title = {Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70006}
}
EUVIMED